Protocol Ledger

NCT05075824 · Phase II · COMPLETED

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Interventional Phase II clinical trial protocol NCT05075824 sponsored by Roche / Genentech in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-09 Enrollment: 95 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05075824
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)95 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05075824
Protocol FieldVerified Registry Value
NCT IdentifierNCT05075824
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment95 participants (ACTUAL)
Registered Start Date2022-03-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05075824
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
East Carolina UniversityGreenville, NCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI